- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 23, 2022Robins Kaplan’s Antitrust Class Action Practice Recognized as Leader In The Field For Fourth Consecutive Year
-
June 17, 2022Robins Kaplan Secures Complete Dismissal of $160 Million Copyright and Software License Dispute
-
June 13, 2022Robins Kaplan Wins Judgment Vacating Two Confessions of Judgment Totaling Nearly $20 Million
-
July 25, 2022Tee It Up for the Troops
-
September 22, 202220th Annual Golf Tournament
-
June 21, 2022How To Oppose An Extension If You Really Need To
-
June 7, 2022Damned if You Do,
Damned if You Don’t -
June 7, 2022Take-Home COVID: The New Frontier?
-
June 24, 2022Biggest US Banks Sail Through Latest Round of Fed Stress Testing
-
June 23, 2022Powell Admits Recession Possible, Sees Tricky Path to Soft Landing
-
June 22, 2022Meta Reaches Settlement With Feds Over Allegedly Discriminatory Housing Ads
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Robins Kaplan Takes a Leading Role in the Expanding Litigation over Benicar and Severe Gastrointestinal Injuries
June 3, 2015
Olmesartan medoxomil is a popular prescription blood pressure medication marketed as Benicar®, Benicar HCT®, Azor®, or Tribenzor®. In July of 2013 the FDA issued a Safety Announcement warning that the drug can cause intestinal problems known as sprue-like enteropathy and required the manufacturer to change its label to warn of this potential injury.1
Symptoms of sprue-like enteropathy include chronic diarrhea, weight loss, nausea and vomiting.2 These symptoms can be so severe that they require hospitalization for dehydration, kidney failure, and malnourishment.3 An August 2012 Mayo Clinic study found a possible association between the drug and sprue-like enteropathy, and further found that when removed from the drug, all of the patients’ symptoms decreased, and/or resolved completely.4 Since that time, a nationwide French study was published which concluded that olmesartan “causes a severe and potentially life threatening enteropathy,” which is much more common with olmesartan than with other drugs in the same class 5
Robins Kaplan LLP has filed dozens of cases against the manufacturer in both Federal and New Jersey State Court. In April of 2015, the federal court cases were consolidated into an MDL (multidistrict litigation) in the District of New Jersey before the Honorable Robert Kugler.6 In one of the Court’s first orders, Judge Kugler appointed Robins Kaplan partner Tara Sutton to the Plaintiff’s Executive Committee. Ms. Sutton will also Chair the Science Committee. Other Robins Kaplan members appointed to leadership positions include Gary Wilson, Science Committee; Rayna Kessler, State Court Liaison; and Holly Dolejsi, Bellwether Selection Committee. Most recently, Robins Kaplan educated the Court on the scientific principles underlying this case. On May 8, 2015, Tara Sutton gave a Science Day presentation to the Judges presiding over the State and Federal Court Litigations.
1 http://www.fda.gov/Drugs/DrugSafety/ucm359477.htm
2 http://www.ncbi.nlm.nih.gov/pubmed/22728033
3 Id.
4 Id.
5 L. Marthey, G. Cadiot, et al. Olmesartan-associated Enteropathy: Results of a National Survey. Ailment. Pharmacol. Ther. (Aug. 2014).
6 http://www.jpml.uscourts.gov/sites/jpml/files/MDL-2606-Initial_Transfer-03-15.pdf
Related Professionals
Holly H. Dolejsi
Partner
Deputy Chair, Mass Tort, Personal Injury and Medical Malpractice Groups
Chair, Women of Robins Kaplan Resource Group
Pronouns: she/her
Rayna E. Kessler
Partner
Gary L. Wilson
Partner
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.